OcuMension secures Alcon eye drop rights with 16.7% stake, marking major strategic shift
OcuMension Therapeutics has struck a landmark deal with Alcon Inc., acquiring commercialization rights for a portfolio of eye care products in China. In exchange, OcuMension will issue 139,161,120 shares to Alcon, amounting to a 16.7% stake in the company. This strategic partnership marks a significant move for OcuMension, making Alcon one of its largest shareholders […]